Quality improvement project to enhance heparin safety in patients with haemodialysis in China

BMJ Open Qual. 2022 Apr;11(2):e001665. doi: 10.1136/bmjoq-2021-001665.

Authors

Qiu-Zhen Tan¹, Yan-Fen Mai¹, Hai-Hong Jiao¹, Ren-Jie Xiong¹, Yu Liu¹, Li Lin², Li-Wen Cui¹, Pearl Pai^{3

4}

Affiliations

¹ Department of Medicine, Division of Nephrology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
² Clinical Service Department, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
³ Department of Medicine, Division of Nephrology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China ppai1@hku.hk.
⁴ Department of Medicine, Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

No abstract available

Keywords: Incident reporting; Medication safety; Patient safety; Quality improvement; Root cause analysis.

MeSH terms

Anticoagulants / adverse effects
China
Heparin* / adverse effects
Humans
Quality Improvement*
Renal Dialysis

Substances

Anticoagulants
Heparin